Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Parallel conduction of the phase I preventive and therapeutic trials based on the Tat vaccine candidate.
Bellino S, Francavilla V, Longo O, Tripiciano A, Paniccia G, Arancio A, Fiorelli V, Scoglio A, Collacchi B, Campagna M, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B. Bellino S, et al. Rev Recent Clin Trials. 2009 Sep;4(3):195-204. doi: 10.2174/157488709789957529. Rev Recent Clin Trials. 2009. PMID: 20028332 Review.
Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.
Longo O, Tripiciano A, Fiorelli V, Bellino S, Scoglio A, Collacchi B, Alvarez MJ, Francavilla V, Arancio A, Paniccia G, Lazzarin A, Tambussi G, Din CT, Visintini R, Narciso P, Antinori A, D'Offizi G, Giulianelli M, Carta M, Di Carlo A, Palamara G, Giuliani M, Laguardia ME, Monini P, Magnani M, Ensoli F, Ensoli B. Longo O, et al. Among authors: bellino s. Vaccine. 2009 May 26;27(25-26):3306-12. doi: 10.1016/j.vaccine.2009.01.090. Epub 2009 Feb 7. Vaccine. 2009. PMID: 19208456 Clinical Trial.
HIV-1 Tat addresses dendritic cells to induce a predominant Th1-type adaptive immune response that appears prevalent in the asymptomatic stage of infection.
Fanales-Belasio E, Moretti S, Fiorelli V, Tripiciano A, Pavone Cossut MR, Scoglio A, Collacchi B, Nappi F, Macchia I, Bellino S, Francavilla V, Caputo A, Barillari G, Magnani M, Laguardia ME, Cafaro A, Titti F, Monini P, Ensoli F, Ensoli B. Fanales-Belasio E, et al. Among authors: bellino s. J Immunol. 2009 Mar 1;182(5):2888-97. doi: 10.4049/jimmunol.0711406. J Immunol. 2009. PMID: 19234184
Containment of infection in tat vaccinated monkeys after rechallenge with a higher dose of SHIV89.6P(cy243).
Borsetti A, Baroncelli S, Maggiorella MT, Moretti S, Fanales-Belasio E, Sernicola L, Tripiciano A, Macchia I, Michelini Z, Belli R, Farcomeni S, Pavone-Cossut MR, Negri D, Caputo A, Bellino S, Butto S, Titti F, Cafaro A, Ensoli B. Borsetti A, et al. Among authors: bellino s. Viral Immunol. 2009 Apr;22(2):117-24. doi: 10.1089/vim.2008.0082. Viral Immunol. 2009. PMID: 19326998
The preventive phase I trial with the HIV-1 Tat-based vaccine.
Ensoli B, Fiorelli V, Ensoli F, Lazzarin A, Visintini R, Narciso P, Di Carlo A, Tripiciano A, Longo O, Bellino S, Francavilla V, Paniccia G, Arancio A, Scoglio A, Collacchi B, Ruiz Alvarez MJ, Tambussi G, Tassan Din C, Palamara G, Latini A, Antinori A, D'Offizi G, Giuliani M, Giulianelli M, Carta M, Monini P, Magnani M, Garaci E. Ensoli B, et al. Among authors: bellino s. Vaccine. 2009 Dec 11;28(2):371-8. doi: 10.1016/j.vaccine.2009.10.038. Epub 2009 Oct 29. Vaccine. 2009. PMID: 19879233 Clinical Trial.
Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.
Cafaro A, Bellino S, Titti F, Maggiorella MT, Sernicola L, Wiseman RW, Venzon D, Karl JA, O'Connor D, Monini P, Robert-Guroff M, Ensoli B. Cafaro A, et al. Among authors: bellino s. J Virol. 2010 Sep;84(17):8953-8. doi: 10.1128/JVI.00377-10. Epub 2010 Jun 16. J Virol. 2010. PMID: 20554774 Free PMC article.
144 results